Milsaperidone (VHX-896) vs Risperidone (QUAR)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Milsaperidone (VHX-896)

Marketed by Vanda Pharmaceuticals

Approved in Schizophreniasmall molecule
Weak signal

NCT06494397 · Phase 1 · completed

Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.

No aligned efficacy figure on record for this race.

Risperidone (QUAR)

Developed by Laboratorios Farmacéuticos Rovi, S.A.

Phase 1 in Schizophreniasmall molecule
Weak signal

NCT06276361 · Phase 1 · completed

A sequential, open-label pharmacokinetic study of quarterly-injection risperidone in 58 participants, with pharmacokinetic parameters as the primary measures. The design is uncontrolled for treatment effect and no results have been posted to the registry, so this is weak evidence.

No aligned efficacy figure on record for this race.

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointMilsaperidone (VHX-896)Risperidone (QUAR)
PANSS total, change—Not reported—Not posted · NCT00159770
CGI-S, change—Not reported—Not posted · NCT00159770
PANSS response—Not reported—Not posted · NCT00159770
PSP, change—Not reported—Not posted · NCT00159770
Relapse (% of patients)—Not reported—Not posted · NCT00159770

PANSS total, change

Milsaperidone (VHX-896)
—Not reported
Risperidone (QUAR)
—Not posted · NCT00159770

CGI-S, change

Milsaperidone (VHX-896)
—Not reported
Risperidone (QUAR)
—Not posted · NCT00159770

PANSS response

Milsaperidone (VHX-896)
—Not reported
Risperidone (QUAR)
—Not posted · NCT00159770

PSP, change

Milsaperidone (VHX-896)
—Not reported
Risperidone (QUAR)
—Not posted · NCT00159770

Relapse (% of patients)

Milsaperidone (VHX-896)
—Not reported
Risperidone (QUAR)
—Not posted · NCT00159770
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Milsaperidone (VHX-896): no structured comparison results are available for Schizophrenia.

Risperidone (QUAR): no structured comparison results are available for Schizophrenia.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Milsaperidone (VHX-896)'s landscape · Risperidone (QUAR)'s landscape